Poïesis is focused on sourcing late-stage or approved products from human R&D and evaluating their viability for in-licensing to develop for the veterinary market

Poïesis has agreed to licensing terms and/or is reviewing opportunities to acquire the veterinary IP rights for assets focused on the treatment of kidney disease, ophthalmic conditions, dermatitis, immune dysfunction, oncology, vascular disease, and systemic fungal infections.

We are working closely with the biotechnology companies that are developing these products for use in humans, which allows Poïesis unprecedented access to data and drug product for clinical trials.

We continue to evaluate novel therapeutics that we encounter which may address unmet or poorly served needs in the pet medicines market.